The introduction of TKIs has dramatically improved disease outcome in patients with CML and has replaced interferon-alpha (IFN-α) and SCT as frontline therapy (99). This evidence concerns the gene IFNA1 and chronic myelogenous leukemia, BCR-ABL1 positive.